Greenwich LifeSciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 7
- Market Cap
- $183.8M
- Introduction
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Cancer Immunotherapy Market Research Report 2025-2029
The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.
Greenwich LifeSciences, Inc. Partners With Italian Clinical Sites For Phase III FLAMINGO-01
Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.
Greenwich LifeSciences Partners with GIM in Italy
Greenwich LifeSciences partners with Italy's Gruppo Italiano Mammella (GIM) for Phase III FLAMINGO-01 trial, involving nine top GIM institutions and over 500 investigators to test GLSI-100 immunotherapy for breast cancer recurrence prevention. Patient enrollment has begun in Italy, addressing significant medical need with 58,160 new breast cancer cases in 2022.
Greenwich LifeSciences Provides Update on Corporate Events
Greenwich LifeSciences updates on 2024 events, including conferences and sponsorships, and details its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy targeting HER2+ breast cancer recurrence.
© Copyright 2025. All Rights Reserved by MedPath